Sotrastaurin

Drug Profile

Sotrastaurin

Alternative Names: AEB 071; NVP-AEB071; Sotrastaurin acetate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; Ohio State University
  • Developer Novartis
  • Class Piperazines; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action Immunosuppressants; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Uveal melanoma
  • Discontinued Liver transplant rejection; Psoriasis; Renal transplant rejection; Transplant rejection; Ulcerative colitis; Uveitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Uveal-melanoma(Metastatic disease) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma in Spain (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top